## Amendments to the Claims:

The following listing of claims will replace all prior versions of the claims in the application referenced above.

## **Listing of Claims:**

Claims 1-21 (canceled)

Claim 22 (new): A composition comprising a daily dose of a valproate compound wherein the composition, when given once a day, provides a mean steady-state AUC<sub>0-24</sub> measurement of valproate that is at least 80% of the mean steady-state AUC<sub>0-24</sub> measurement of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 23 (new): The composition of claim 22 wherein the valproate compound is divalproex sodium.

Claim 24 (new): The composition of claim 23 wherein the composition further provides a mean steady-state Cmax of valproate that is statistically significantly lower than the mean steady-state Cmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 25 (new): The composition of claim 23 wherein the mean steady-state degree of fluctuation of valproate provided by the composition is less than the mean steady-state degree of fluctuation of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 26 (new): The composition of claim 23 wherein the mean steady-state Tmax of valproate provided by the composition is at least twice as long as the mean steady-state Tmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 27 (new): The composition of claim 23 wherein the mean steady-state Cmin of valproate provided by the composition is not statistically different than the mean steady-state Cmin of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 28 (new): The composition of claim 23 wherein the daily dose of divalproex sodium is provided by one or more dosage units containing, in combination, the daily dose of divalproex sodium.

Claim 29 (new): The composition of claim 28 wherein the daily dose is 1000 mg of divalproex sodium.

Claim 30 (new): The composition of claim 28 wherein the daily dose is 500 mg of divalproex sodium.

Claim 31 (new): The composition of claim 28 wherein the daily dose is 250 mg of divalproex sodium.

Claim 32 (new): A composition comprising a daily dose of a valproate compound wherein the composition, when given once a day, provides a mean steady-state Cmax of valproate that is statistically significantly lower than the mean steady-state Cmax of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 33 (new): The composition of claim 32 wherein the valproate compound is divalproex sodium.

Claim 34 (new): The composition of claim 33 wherein the mean steady-state degree of fluctuation of valproate provided by the composition is less than the mean steady-state degree of fluctuation of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 35 (new): The composition of claim 33 wherein the mean steady-state Tmax of valproate provided by the composition is at least twice as long as the mean steady-state Tmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 36 (new): The composition of claim 33 wherein the mean steady-state Cmin of valproate provided by the composition is not statistically different than the mean steady-state Cmin of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 37 (new): The composition of claim 33 wherein the daily dose of divalproex sodium is provided by one or more dosage units containing, in combination, the daily dose of divalproex sodium.

Claim 38 (new): The composition of claim 37 wherein the daily dose is 1000 mg of divalproex sodium.

Claim 39 (new): The composition of claim 37 wherein the daily dose is 500 mg of divalproex sodium.

Claim 40 (new): The composition of claim 37 wherein the daily dose is 250 mg of divalproex sodium.

Claim 41 (new): The composition of claim 33 wherein the mean steady-state Cmax of valproate provided by the composition is 10% to 20% lower than the mean steady-state Cmax provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 42 (new): A method of reducing the side effects associated with the administration of a valproate compound to a patient comprising administering a composition comprising a daily dose of a valproate compound wherein the composition, when given once a day, provides a mean steady-state AUC<sub>0.24</sub> measurement of valproate that is at least 80% of the mean steady-state

 $AUC_{0-24}$  measurement of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 43 (new): The method of claim 42 wherein the composition provides a mean steady-state Cmax of valproate that is statistically significantly lower than the mean steady-state Cmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 44 (new): A method of treating a member of the group consisting of bipolar disorders, epilepsy, and migraine headache comprising administering a composition comprising a daily dose of divalproex sodium wherein the composition, when given once a day, provides a mean steady-state  $AUC_{0-24}$  measurement of valproate that is at least 80% of the mean steady-state  $AUC_{0-24}$  measurement of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 45 (new): The method of claim 44 wherein the composition provides a mean steady-state Cmax of valproate that is statistically significantly lower than the mean steady-state Cmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.